American Clinical Laboratory Association Elects Officers for 2023-2024 Board of Directors
Washington, D.C. – The American Clinical Laboratory Association (ACLA) announced the election of its Board officers for 2023-2024, confirmed by a membership vote today at the Association’s annual meeting.
William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, was re-elected ACLA Board Chair for a second term. Jerry Hussong, M.D.,M.B.A., CEO of Sonic Healthcare USA, and Adam Schechter, president, chairman and CEO of Labcorp, were re-elected Vice Chairs. Kevin Conroy, chairman and CEO of Exact Sciences Corporation, was elected Treasurer.
“Dr. Morice’s leadership and depth of expertise have been invaluable assets to the ACLA team and our membership as a whole,” said Susan Van Meter, president of ACLA. “It is a privilege to work in collaboration with him and board officers Dr. Hussong and Messrs. Schechter and Conroy to advance advocacy priorities on behalf of the clinical laboratory industry and the patients and providers we serve. Together, we are committed to achieving our advocacy priorities that include securing long term Medicare payment reform for clinical laboratories through passage of the Saving Access to Laboratory Services Act (SALSA) this year. We are also focused on advancing reimbursement, regulatory and preparedness policies that support innovation and bolster both the nation’s clinical laboratory infrastructure and workforce to ensure access to laboratory testing services that improve and save lives.”
To view the full list of ACLA’s board members, click here.
The American Clinical Laboratory Association (ACLA) is the national trade association representing leading laboratories that deliver essential diagnostic health information to patients and providers. ACLA members are at the forefront of driving diagnostic innovation to meet the country’s evolving health care needs and provide vital clinical laboratory tests that identify and prevent infectious, acute, and chronic disease. ACLA works to advance the next generation of health care delivery through policies that expand access to lifesaving testing services.